Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

GILD

Gilead Sciences Inc

NASDAQ

77.65

+1.05

+1.37%

After Hours: 77.65 0 0.00% 19:35 12/01 EST

OPEN

76.78

PREV CLOSE

76.60

HIGH

77.66

LOW

76.20

VOLUME

5.40M

TURNOVER

52 WEEK HIGH

89.74

52 WEEK LOW

72.54

MARKET CAP

96.76B

P/E (TTM)

16.65

2 Biotech Stocks You Can Buy and Hold for the Next Decade

Two biotech stocks can provide solid returns through the next decade. Sanofi and gilead sciences are two companies that can continue to innovate and develop new medicines. Sanilly's recent sell-off is overdone; the company's new products should be a growth driver in the future. Gilead sciences is a leader in the hiv market.

The Motley Fool · 1d ago

Piper Sandler Reaffirms Their Buy Rating on Gilead Sciences (GILD)

TipRanks · 2d ago

Biogen: LAQEMBI's $10 Billion Potential

Biogen's latest alzheimer's drug, aduhelm, faced challenges after fda approval. The company's latest drug, a new type of alzheimer's treatment, has raised concerns. Biogen has a $10 billion potential, according to main street investor's analysis of the stock.

Seeking Alpha · 2d ago

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

NASDAQ · 2d ago

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies

Fda says it has received reports of patients developing t-cell malignancies. The agency says the risk applies to all car-t therapies approved by the fda since 2017. Six car t- cell therapies have been approved for use in the u.s., the agency says.

Benzinga · 2d ago

Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

Fda says it is investigating cancer risks associated with car-t cell therapies. Shares of smaller biotech companies involved in developing the therapies plunged tuesday. The fda is investigating all currently approved products in the class of cancer-fighting therapies.car-t therapies alter immune cells so they can attack cancer cells.

MarketWatch · 3d ago

Gilead After Q3 2023 Earnings: Grading Its Top Cancer Acquisition

Gilead's $21 billion 2020 acquisition of immunomedics has generated growing revenues from trodelvy. Trodelvy is a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer. Revenues from the deal have been modest but the company has significant potential in the future. Gilead expects to produce 1/3 of its revenue from oncology by 2030.

Seeking Alpha · 3d ago

Gilead Sciences Says It Has Fully Cooperated With The U.S. FDA's Request For An Analysis Of Our Data Related To The FDA's Inquiry

Benzinga · 3d ago

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Webull offers Gilead Sciences, Inc. stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.